{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:37:16Z","timestamp":1794062236916,"version":"4.8.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["T32 EY024236"],"award-info":[{"award-number":["T32 EY024236"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["P30EY025585(BA-A)"],"award-info":[{"award-number":["P30EY025585(BA-A)"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["P30EY025585(BA-A),"],"award-info":[{"award-number":["P30EY025585(BA-A),"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41433-024-03531-1","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T14:05:14Z","timestamp":1734012314000},"page":"1107-1114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Risk of audiologic side effects with teprotumumab treatment for thyroid eye disease: propensity matched analysis"],"prefix":"10.1038","volume":"39","author":[{"given":"Jonathan C.","family":"Markle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Johanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline K.","family":"Shaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-8162","authenticated-orcid":false,"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"3531_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.615993","volume":"11","author":"L Bartalena","year":"2020","unstructured":"Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy. Front Endocrinol. 2020;11:615993. https:\/\/doi.org\/10.3389\/fendo.2020.615993","journal-title":"Front Endocrinol"},{"key":"3531_CR2","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith TJ, Heged\u00fcs L. Graves\u2019 disease. Longo DL, ed. N Engl J Med. 2016;375:1552\u201365. https:\/\/doi.org\/10.1056\/NEJMra1510030","journal-title":"N Engl J Med"},{"key":"3531_CR3","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","volume":"170","author":"J Pritchard","year":"2003","unstructured":"Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003;170:6348\u201354. https:\/\/doi.org\/10.4049\/jimmunol.170.12.6348","journal-title":"J Immunol"},{"key":"3531_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R. et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1910434.","journal-title":"N Engl J Med"},{"key":"3531_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10911-008-9104-6","volume":"13","author":"SJ Weroha","year":"2008","unstructured":"Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials\u2014early lessons. J Mammary Gland Biol Neoplasia. 2008;13:471\u201383. https:\/\/doi.org\/10.1007\/s10911-008-9104-6","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"3531_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.heares.2003.12.022","volume":"196","author":"I Varela-Nieto","year":"2004","unstructured":"Varela-Nieto I, Morales-Garcia JA, Vigil P, Diaz-Casares A, Gorospe I, S\u00e1nchez-Galiano S. et al. Trophic effects of insulin-like growth factor-I (IGF-I) in the inner ear. Hear Res. 2004;196:19\u201325. https:\/\/doi.org\/10.1016\/j.heares.2003.12.022.","journal-title":"Hear Res"},{"key":"3531_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3389\/fnagi.2017.00411","volume":"9","author":"L Rodr\u00edguez-de La Rosa","year":"2017","unstructured":"Rodr\u00edguez-de La Rosa L, Lassaletta L, Calvino M, Murillo-Cuesta S, Varela-Nieto I. The role of insulin-like growth factor 1 in the progression of age-related hearing loss. Front Aging Neurosci. 2017;9:411. https:\/\/doi.org\/10.3389\/fnagi.2017.00411","journal-title":"Front Aging Neurosci"},{"key":"3531_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1460-9568.2005.04584.x","volume":"23","author":"R Cediel","year":"2006","unstructured":"Cediel R, Riquelme R, Contreras J, D\u00edaz A, Varela-Nieto I. Sensorineural hearing loss in insulin-like growth factor I-null mice: a new model of human deafness: Hearing loss in Igf-1-mutant mice. Eur J Neurosci. 2006;23:587\u201390. https:\/\/doi.org\/10.1111\/j.1460-9568.2005.04584.x","journal-title":"Eur J Neurosci"},{"key":"3531_CR9","unstructured":"761143s000lbl.pdf. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761143s000lbl.pdf"},{"key":"3531_CR10","unstructured":"Teprotumumab - EyeWiki. https:\/\/eyewiki.org\/Teprotumumab"},{"key":"3531_CR11","doi-asserted-by":"publisher","first-page":"e248335","DOI":"10.1136\/bcr-2021-248335","volume":"15","author":"A Chow","year":"2022","unstructured":"Chow A, Silkiss RZ. Teprotumumab-associated chronic hearing loss screening and proposed treatments. BMJ Case Rep. 2022;15:e248335 https:\/\/doi.org\/10.1136\/bcr-2021-248335","journal-title":"BMJ Case Rep"},{"key":"3531_CR12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/00034894211042740","volume":"131","author":"J Highland","year":"2022","unstructured":"Highland J, Gordon S, Reddy D, Patel N. Ototoxicity and teprotumumab. Ann Otol Rhinol Laryngol. 2022;131:910\u20133. https:\/\/doi.org\/10.1177\/00034894211042740","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"3531_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","volume":"240","author":"CM Sears","year":"2022","unstructured":"Sears CM, Azad AD, Amarikwa L, Pham BH, Men CJ, Kaplan DN. et al. Hearing dysfunction after treatment with teprotumumab for thyroid eye disease. Am J Ophthalmol. 2022;240:1\u201313. https:\/\/doi.org\/10.1016\/j.ajo.2022.02.015.","journal-title":"Am J Ophthalmol"},{"key":"3531_CR14","doi-asserted-by":"publisher","unstructured":"Keen JA, Correa T, Pham C, Claussen AD, Hansen MR, Carter KD, et al. Frequency and patterns of hearing dysfunction in patients treated with teprotumumab. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2023.08.001","DOI":"10.1016\/j.ophtha.2023.08.001"},{"key":"3531_CR15","unstructured":"STROBE_checklist_v4_combined.pdf. https:\/\/www.equator-network.org\/wp-content\/uploads\/2015\/10\/STROBE_checklist_v4_combined.pdf"},{"key":"3531_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ajo.2023.04.013","volume":"253","author":"S Ramesh","year":"2023","unstructured":"Ramesh S, Zhang Q, ed, Sharpe J, Penne R, Haller J, Lum F. et al. Thyroid eye disease and its vision-threatening manifestations in the academy IRIS registry: 2014-2018. Am J Ophthalmol. 2023;253:74\u201385. https:\/\/doi.org\/10.1016\/j.ajo.2023.04.013.","journal-title":"Am J Ophthalmol"},{"key":"3531_CR17","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","volume":"129","author":"RS Douglas","year":"2022","unstructured":"Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT. et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment. Ophthalmology. 2022;129:438\u201349. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.017.","journal-title":"Ophthalmology"},{"key":"3531_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.aace.2022.01.004","volume":"8","author":"K Shah","year":"2022","unstructured":"Shah K, Charitou M. A novel case of hyperglycemic hyperosmolar state after the use of teprotumumab in a patient with thyroid eye disease. AACE Clin Case Rep. 2022;8:148\u20139. https:\/\/doi.org\/10.1016\/j.aace.2022.01.004","journal-title":"AACE Clin Case Rep"},{"key":"3531_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ajmg.c.31673","volume":"181","author":"\u00c5 Bonnard","year":"2019","unstructured":"Bonnard \u00c5, Bark R, Hederstierna C. Clinical update on sensorineural hearing loss in Turner syndrome and the X\u2010chromosome. Am J Med Genet. 2019;181:67\u201373. https:\/\/doi.org\/10.1002\/ajmg.c.31673","journal-title":"Am J Med Genet"},{"key":"3531_CR20","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3390\/cells10071686","volume":"10","author":"AM Celaya","year":"2021","unstructured":"Celaya AM, Rodr\u00edguez-de La Rosa L, Berm\u00fadez-Mu\u00f1oz JM, Zubeldia JM, Rom\u00e1-Mateo C, Avenda\u00f1o C. et al. IGF-1 haploinsufficiency causes age-related chronic cochlear inflammation and increases noise-induced hearing loss. Cells. 2021;10:1686. https:\/\/doi.org\/10.3390\/cells10071686.","journal-title":"Cells"},{"key":"3531_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.4103\/ijem.IJEM_10_17","volume":"21","author":"K Cherian","year":"2017","unstructured":"Cherian K, Kapoor N, Mathews SS, Paul TV. Review article: endocrine glands and hearing: auditory manifestations of various endocrine and metabolic conditions. Indian J Endocr Metab. 2017;21:464\u20139. https:\/\/doi.org\/10.4103\/ijem.IJEM_10_17","journal-title":"Indian J Endocr Metab"},{"key":"3531_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04526-7","volume":"7","author":"C Lassale","year":"2017","unstructured":"Lassale C, Batty GD, Steptoe A, Zaninotto P. Insulin-like growth factor 1 in relation to future hearing impairment: findings from the English Longitudinal Study of Ageing. Sci Rep. 2017;7:4212. https:\/\/doi.org\/10.1038\/s41598-017-04526-7","journal-title":"Sci Rep"},{"key":"3531_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00405-011-1668-x","volume":"269","author":"J Attias","year":"2012","unstructured":"Attias J, Zarchi O, Nageris BI, Laron Z. Cochlear hearing loss in patients with Laron syndrome. Eur Arch Otorhinolaryngol. 2012;269:461\u20136. https:\/\/doi.org\/10.1007\/s00405-011-1668-x","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"3531_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2020-00057","volume":"8","author":"KL Hayward","year":"2021","unstructured":"Hayward KL, Johnson AL, Horsfall LU, Moser C, Valery PC, Powell EE. Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM. BMJ Open Gastroenterol. 2021;8:e000572. https:\/\/doi.org\/10.1136\/bmjgast-2020-00057.","journal-title":"BMJ Open Gastroenterol"},{"key":"3531_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0361-1","volume":"17","author":"K Burles","year":"2017","unstructured":"Burles K, Innes G, Senior K, Lang E, McRae A. Limitations of pulmonary embolism ICD-10 codes in emergency department administrative data: let the buyer beware. BMC Med Res Methodol. 2017;17:89. https:\/\/doi.org\/10.1186\/s12874-017-0361-1.","journal-title":"BMC Med Res Methodol"},{"key":"3531_CR26","unstructured":"Continuing Your Treatment | TEPEZZA\u00ae (teprotumumab-trbw). https:\/\/www.tepezza.com\/cost-and-support\/completing-treatment"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03531-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03531-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03531-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T13:04:35Z","timestamp":1744117475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03531-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3531"],"URL":"https:\/\/doi.org\/10.1038\/s41433-024-03531-1","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"1 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KET reports personal fees from Genentech\/Roche, Apellis, Alimera, Iveric Bio, Bausch and Lomb, and EyePoint; research fees from Zeiss and Regenxbio. RPS reports personal fees from Genentech\/Roche, Alcon, Novartis, Regeneron, Asclepix, Gyroscope, Bausch and Lomb, and Apellis. All other authors report no disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}